Evolving Landscape of SMA Treatment
In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.
Julie Parsons, MD: We’re thrilled to have 3 disease-modifying therapies, but each agent can be improved on. We can do the 1.0 and 2.0 drug. We still have room for improvement, and we have new drugs being developed that aren’t necessarily SMN-dependent drugs. Maybe we’ll start working on the muscles. Can we increase the force of the muscle and increase strength? Can we do even better for patients? Adult and young adult patients with SMA [spinal muscular atrophy] complain significantly of fatigue as being a problem, and it gets in the way of their life. Is there another agent that we could use to get rid of the fatigue for these patients so that they have the strength and energy to continue to have active, productive lives? It‘s an incredibly exciting time. This is only the beginning. We’ve made amazing changes and have benefited the patients, but there’s still much more to come. We aren’t done.
John Brandsema, MD: Another very important message that we say to any person living with SMA, their caregivers, the payer system, or other colleagues related to this disease is once we know you have SMA, we need you to be established with an SMA-focused care team for your care for life. This is to optimize the standard of care and because these therapies are new. We need to be vigilant to ensure that we’re assessing the short- and long-term aspects of how these therapies impact the disease and their potential complications in a way that gives the best possible outcome for the person living with the disease. This is an important message that needs to be clear in any care plan and any endorsed approach to this disease. We want you to be connected with people who know this disease and know how to best help you.
Transcript edited for clarity.
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
